



## Amyloidosis: Current Status on Diagnosis, Management and Therapeutic Strategies

Guest Editors:

### **Dr. Angela Romano**

1. UOC Neurologia, Fondazione  
Policlinico Universitario Agostino  
Gemelli IRCCS, Rome, Italy  
2. Dipartimento di Neuroscienze,  
Università Cattolica del Sacro  
Cuore, Rome, Italy

### **Dr. Giulia Bisogni**

Centro Clinico NeMO Adulti,  
Fondazione Serena Onlus-  
Fondazione Policlinico  
Universitario Agostino Gemelli  
IRCCS, Rome, Italy

### **Message from the Guest Editors**

Dear Colleagues,

This Special Issue will focus on the state of the art of the diagnosis and management of amyloidosis, with particular emphasis on the assessment of innovative biomarkers for disease diagnosis and monitoring.

Original research articles and reviews are welcome. Articles presenting new strategies supported by experimental or preclinical data will also be considered.

We look forward to receiving your contributions.

Dr. Angela Romano

Dr. Giulia Bisogni

*Guest Editors*

Deadline for manuscript  
submissions:

**closed (20 March 2023)**



[mdpi.com/si/123374](https://mdpi.com/si/123374)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)